茵陈水提物对牛血清白蛋白诱导的肝损伤大鼠的保护作用研究

doi:10.3969/j.issn.1672-5069.2017.01.014

摘要/Abstract

摘要： 目的研究茵陈水提物对牛血清白蛋白所致肝纤维化大鼠的保护作用。方法将90只SD 大鼠随机平均分为正常组、模型组、秋水仙碱组、大剂量（200 mg·kg^-1）、中等剂量（100 mg·kg^-1）和小剂量（50 mg·kg^-1）茵陈水提物处理组。在造模成功后除对照组和模型组外,给予药物灌胃。在末次给药后取各组大鼠血清和肝组织,检测血清Ⅲ型前胶原（PC-Ⅲ）、Ⅳ型胶原（Ⅳ-C）、层粘连蛋白（LN）和透明质酸酶（HA）及肝组织羟脯氨酸含量,观察肝组织病理学变化。结果大剂量药物处理组动物血清ALT、AST、PC-Ⅲ、Ⅳ-C胶原、LN、HA及肝组织羟脯氨酸含量分别为（103.78±19.83） IU/L、（246.53±36.67） IU/L、（30.34±2.52） ng/ml、（29.54±2.65） ng/ml、（45.34±1.45）ng/ml、（232.51±23.66） ng/ml及（0.85±0.22） μg/mg,中剂量组分别为（124.59±24.41） IU/L、（277.23±36.45）IU/L、（34.57±2.34） ng/ml、（34.90±2.45） ng/ml、（52.13±2.34） ng/ml、（283.14±23.75） ng/ml及（0.96±0.26）μg/mg,均明显低于模型组【分别为（161.24±26.23） IU/L、（382.45±39.45） IU/L、（41.78±3.12） ng/ml、（42.34±3.25） ng/ml、（65.14±3.81） ng/ml、（383.53±39.35） ng/ml及（1.43±0.17） μg/mg,P均<0.05】;大和中剂量组ALB水平分别为（35.66±2.85） g/L和（35.78±2.64） g/L,均明显高于模型组【（31.32±2.15） g/L,P均<0.05】;大和中剂量组重度纤维化发生率均为13.3%,均明显低于模型组的93.3%（P均<0.05）;肝组织病理学检查显示,与模型组比,大和中剂量组大鼠肝细胞水肿、变性和坏死情况均显著减轻。结论茵陈水提物具有一定的抗肝纤维化作用,值得进行深入研究。

关键词: 肝纤维化, 茵陈, 牛血清白蛋白, 免疫性肝损伤, 大鼠

Abstract: Objective To study the therapeutic effect of YinChen water extracts in rats with bovine serum albumin-induced liver fibrosis. Methods 90 SD rats were randomly divided into normal control,model,colchicines,and large（200 mg·kg^-1）,middle（100 mg·kg^-1） and low （50 mg·kg^-1） dose of YinChen water extracts intervened groups. The medicine and herbal medicine were intragastricly administered after the model had been successfully established. Serum PC III,IV-C collagen,LN,HA and hepatic hydroxyproline content were detected. The liver histopathological changes were also observed. Results The levels of serum ALT,AST,PC-Ⅲ,Ⅳ-C,LN,HA and liver tissue hydroxyproline content were（103.78±19.83） IU/L,（246.53±36.67） IU/L,（30.34±2.52） ng/ml,（29.54±2.65） ng/ml,（45.34±1.45） ng/ml,（232.51±23.66） ng/ml and （0.85±0.22） μg/mg in the large dose YinChen water extracts group,and they were（124.59±24.41） IU/L,（277.23±36.45） IU/L,（34.57±2.34） ng/ml,（34.90±2.45） ng/mL,（52.13±2.34） ng/ml,（283.14±23.75） ng/ml and（0.96±0.26） μg/mg in the middle dose group, much lower than in the model group[（161.24±26.23） IU/L,（382.45±39.45） IU/L,（41.78±3.12） ng/ml,（42.34±3.25） ng/ml,（65.14±3.81） ng/ml,（383.53±39.35） ng/ml and （1.43±0.17） μg/mg,P<0.05];serum levels of albumin in large and middle groups were （35.66±2.85）g/L and （35.78±2.64）g/L, significantly higher than in the model group[（31.32±2.15）g/L,P<0.05];Pathological examination showed that hepatic cells edema,degeneration and necrosis in colchicines,large and middle dose of YinChen water extract groups appeared significantly improved as compared with in the model group. Conclusion The YinChen water extracts has a certain therapeutic effect on liver fibrosis,and it is worth to be further studied.

Key words: Liver fibrosis, Herbal medicine, Bovine serum albumin, Immunological liver injuries, Rats

吴军, 尚瑞. 茵陈水提物对牛血清白蛋白诱导的肝损伤大鼠的保护作用研究[J]. 实用肝脏病杂志, 2017, 20(1): 51-54.

Wu Jun, Shang Rui.. Protective effects of YinChen water extract in rats with bovine serum albumin-induced hepatic fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 51-54.

参考文献

[1] Ahmad A,Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol,2012,18（3）:155-167.
[2] Ashley B,Zachary G. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev Gastroenterol Hepatol,2012,6（2）:187-198.
[3] Jun DW,Tak WY,Bae SH,et al. Recent trends in the treatment of chronic hepatitis C. Kor J Hepatol,2012,18（1）:22-28.
[4] Sajid M,Khan MR,Shah NA,et al. Proficiencies of artemisia scoparia against CCl4 induced DNA damages and renal toxicity in rat. BMC Complement Altern Med,2016,16（1）:149.
[5] 田代华. 实用中药辞典. 北京:人民卫生出版社,2002:1279.
[6] Khan MA,Khan H,Tariq SA,et al. In vitro attenuation of thermal-induced protein denaturation by aerial parts of Artemisia scoparia. J Evid Based Complement Altern Med. 2015,20（1）:9-12.
[7] Cho JY,Park KH,Hwang do Y,et al. Antihypertensive effects of artemisia scoparia waldst in spontaneously hypertensive rats and identification of angiotensin I converting enzymeinhibitors. Molecules,2015,20（11）:19789-19804.
[8] Richard AJ,Fuller S,Fedorcenco V,et al. Artemisia scoparia enhances adipocyte development and endocrine function in vitro and enhances insulin action in vivo. PLoS One,2014,9（6）:e98897.
[9] 朱启贵,方步武,竺稽能. 牛血清白蛋白致免疫性肝纤维化动物模型的研究. 中西医结合肝病杂志,1992,2:20.
[10] Puche JE,Saiman Y,Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol,2013,3:1473-1492.
[11] Ergelen R,Akyuz U,Aydin Y,et al. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liverdisease. Eur J Gastroenterol Hepatol,2015,27:667-671.
[12] Mak KM,Chen LL,Lee TF. Codistribution of collagen type IV and laminin in liver fibrosis of elderly cadavers:immunohistochemical marker of perisinusoidal basement membrane formation. Anat Rec （Hoboken）,2013,296:953-964.
[13] Wang ZQ,Zhang XH,Yu Y,et al. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. Metabolism.,2013,62（9）:1239-1249.
[14] Habib M,Waheed I. Evaluation of anti-nociceptive,anti-inflammatory and antipyretic activities of Artemisia scopariahydromethanolic extract. J Ethnopharmacol. 2013,145（1）:18-24.
[15] Choi E,Park H,Lee J,et al. Anticancer,antiobesity,and anti-inflammatory activity of Artemisia species in vitro. J Tradit Chin Med,2013,33（1）:92-97.
[16] Sharopov FS,Setzer WN. The essential oil of Artemisia scoparia from tajikistan is dominated by phenyldiacetylenes. Nat Prod Commun,2011,6（1）:119-122.
[17] Takami T,Terai SJ,Sakaida I. Current state and future prospects for our liver regeneration therapy using autologous bone marrow cells for decompensated liver cirrhosis patients. J Pharmacol Sci,2011,115（3）:274-278.
[18] Mathurin P,O’Grady J,Carithers RL,et al. Corticosteroids improve short -term survival in patients with severe alcoholic hepatitis:meta-analysis of individual patient data. Gut,2011,60（2）:255-260.
[19] Kim KA,Jeong SH. The diagnosis and treatment of primary biliary cirrhosis. Kor J Hepatol,2011,17（3）:173-179.
[20] 王美玲,陆伦根. 肝纤维化治疗研究进展. 实用肝脏病杂志, 2013,16（4）:369-371.